Every 10-Q that Harrow Health Inc (HROW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HROW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HROW filings page.
Harrow, Inc. reported higher revenue but significantly weaker profitability for the quarter ended June 30, 2026. Total revenues rose to $70.7 million from $63.7 million, driven by Branded products, which grew to $56.1 million, while Compounding revenue declined to $14.6 million. VEVYE revenue more than doubled year over year for the quarter to $29.4 million, and other branded products also increased, partially offset by lower IHEEZO sales.
Despite growth in Branded revenue, profitability deteriorated. Harrow recorded a net loss of $17.3 million for the quarter versus net income of $5.0 million a year earlier, and a six‑month net loss of $44.9 million. Gross margins contracted in both Branded and Compounding segments, while selling, general and administrative expenses increased to $53.3 million for the quarter and research and development rose to $8.1 million, reflecting higher headcount, stock‑based compensation, and clinical activity.
Leverage and cash flows shifted meaningfully. Notes payable, net, increased to $292.4 million after issuing an additional $50.0 million of 8.625% Senior Notes due 2030, contributing to total liabilities of $402.0 million and reducing total stockholders’ equity to $14.8 million. Operating activities used $18.7 million of cash in the first half, compared with positive $18.9 million in the prior‑year period, though cash and cash equivalents rose to $83.9 million. Subsequent to quarter‑end, Harrow agreed to acquire global rights to TYRVAYA for $30.0 million upfront plus up to $70.0 million in milestones.
Harrow, Inc. reported softer results for the quarter ended March 31, 2026. Total revenues were $44.2 million, down from $47.8 million a year earlier, as branded product sales grew but compounding revenues declined sharply, including the prior discontinuation of Klarity-C.
Branded revenue rose to $30.7 million, led by VEVYE at $20.9 million, while IHEEZO sales fell. Compounding revenue dropped to $13.5 million. Higher selling, general and administrative spending and increased R&D pushed the net loss to $27.6 million, compared with $17.8 million in the prior-year quarter.
Harrow ended the quarter with $94.6 million in cash and cash equivalents, helped by issuing an additional $50 million of 8.625% Senior Notes due 2030, bringing total notes payable, net, to $292.1 million. Operating cash flow swung to an outflow of $9.0 million from an inflow of $19.7 million a year earlier.
Harrow, Inc. (HROW) reported Q3 2025 results, showing strong top-line growth and a swing to profitability for the quarter while executing a major refinancing. Revenue rose to $71.6 million from $49.3 million a year ago, driven mainly by product sales of $71.5 million. Gross profit reached $53.9 million. Operating income was $14.7 million, and net income was $1.0 million (diluted EPS $0.03) versus a prior-year loss.
Year to date, Harrow recorded a net loss of $11.8 million, reflecting higher interest expense and a $7.8 million loss on extinguishment of debt tied to balance sheet changes. The company issued $250.0 million of 8.625% senior notes due 2030 and repaid its Oaktree Loan and 2026/2027 notes in September. Cash and cash equivalents were $74.3 million at quarter end, supported by $35.5 million net cash provided by operating activities for the first nine months of 2025. Shares outstanding were 37,037,453 as of November 10, 2025.
Harrow, Inc. reported stronger product sales and improved operating performance for the quarter and six months ended June 30, 2025. Product sales for the three months were $63,657,000 compared with $48,871,000 a year earlier, and total revenues for the three months were $63,742,000 versus $48,939,000. Gross profit for the quarter was $47,512,000, driving a GAAP net income of $4,995,000 for the three months ended June 30, 2025, compared with a net loss of $6,473,000 in the prior-year quarter.
For the six months ended June 30, 2025, total revenues were $111,573,000 versus $83,526,000 a year earlier and the company reported a net loss of $12,785,000, an improvement from a $20,038,000 loss in the prior-year period. Cash and cash equivalents increased to $52,963,000 and operating activities provided $18,865,000 of cash during the six months. Material near-term financing items exist: the Oaktree Loan ($107,500,000 principal) and the 2026 Notes ($75,000,000) mature in January and April 2026, and management is pursuing refinancing or asset sales but notes there is no assurance of success, stating these maturities could raise substantial doubt about the company’s ability to continue as a going concern.